Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Bacteremia | 3 | 2021 | 1372 | 0.86 | Why? |
| Point-of-Care Testing | 4 | 2021 | 2782 | 0.85 | Why? |
| Eye Infections, Bacterial | 1 | 2019 | 86 | 0.73 | Why? |
| beta-Glucans | 1 | 2018 | 176 | 0.62 | Why? |
| Mycoses | 2 | 2020 | 589 | 0.55 | Why? |
| Sputum | 1 | 2021 | 1720 | 0.49 | Why? |
| Ageusia | 1 | 2020 | 918 | 0.47 | Why? |
| Drug Resistance, Microbial | 4 | 2020 | 419 | 0.47 | Why? |
| Anti-Infective Agents | 6 | 2021 | 1766 | 0.44 | Why? |
| Antimicrobial Stewardship | 5 | 2020 | 931 | 0.44 | Why? |
| London | 5 | 2021 | 2166 | 0.43 | Why? |
| Secondary Care | 3 | 2021 | 160 | 0.42 | Why? |
| Bacteria | 1 | 2021 | 1897 | 0.41 | Why? |
| Drug Resistance, Bacterial | 1 | 2019 | 1414 | 0.39 | Why? |
| Bacterial Infections | 3 | 2020 | 2229 | 0.36 | Why? |
| Reagent Kits, Diagnostic | 1 | 2018 | 2149 | 0.34 | Why? |
| Anti-Bacterial Agents | 6 | 2019 | 10083 | 0.33 | Why? |
| Serologic Tests | 1 | 2021 | 4359 | 0.32 | Why? |
| Inpatients | 1 | 2021 | 5161 | 0.28 | Why? |
| United Kingdom | 9 | 2021 | 18046 | 0.26 | Why? |
| Decision Support Systems, Clinical | 3 | 2017 | 551 | 0.26 | Why? |
| Drug Prescriptions | 3 | 2020 | 1062 | 0.23 | Why? |
| Chlamydophila pneumoniae | 1 | 2021 | 98 | 0.21 | Why? |
| Coinfection | 4 | 2021 | 6820 | 0.21 | Why? |
| Gene-Environment Interaction | 1 | 2020 | 127 | 0.20 | Why? |
| Shoulder Joint | 1 | 2019 | 57 | 0.19 | Why? |
| Respiratory Tract Infections | 1 | 2020 | 6817 | 0.19 | Why? |
| Staphylococcus | 1 | 2019 | 77 | 0.19 | Why? |
| Patient Medication Knowledge | 1 | 2018 | 13 | 0.18 | Why? |
| Floxacillin | 1 | 2018 | 14 | 0.18 | Why? |
| Arthritis, Infectious | 1 | 2019 | 111 | 0.18 | Why? |
| Tetanus | 1 | 2018 | 61 | 0.17 | Why? |
| Proteoglycans | 1 | 2018 | 130 | 0.17 | Why? |
| Blogging | 1 | 2017 | 44 | 0.16 | Why? |
| Skin Diseases, Bacterial | 1 | 2018 | 105 | 0.16 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.16 | Why? |
| Soft Tissue Infections | 1 | 2018 | 116 | 0.16 | Why? |
| Immunoassay | 3 | 2021 | 4485 | 0.16 | Why? |
| Support Vector Machine | 1 | 2017 | 330 | 0.15 | Why? |
| Pathology, Molecular | 1 | 2019 | 343 | 0.15 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.15 | Why? |
| Immunologic Tests | 1 | 2018 | 445 | 0.14 | Why? |
| Microbiology | 1 | 2017 | 134 | 0.14 | Why? |
| Vancomycin | 1 | 2018 | 328 | 0.14 | Why? |
| Pandemics | 12 | 2021 | 389249 | 0.14 | Why? |
| Retrospective Studies | 9 | 2021 | 105322 | 0.13 | Why? |
| Humans | 36 | 2021 | 930598 | 0.13 | Why? |
| Candidemia | 1 | 2018 | 353 | 0.13 | Why? |
| Limit of Detection | 1 | 2021 | 2698 | 0.12 | Why? |
| Hospitals, Teaching | 2 | 2020 | 1609 | 0.12 | Why? |
| Aged, 80 and over | 8 | 2021 | 88759 | 0.12 | Why? |
| Middle Aged | 16 | 2021 | 270681 | 0.12 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 711 | 0.12 | Why? |
| Betacoronavirus | 7 | 2020 | 204454 | 0.12 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.12 | Why? |
| Communicable Diseases | 2 | 2017 | 2148 | 0.12 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.11 | Why? |
| Practice Patterns, Physicians' | 3 | 2019 | 4927 | 0.11 | Why? |
| Health Services Research | 1 | 2017 | 756 | 0.11 | Why? |
| Microbial Sensitivity Tests | 1 | 2019 | 2886 | 0.10 | Why? |
| Male | 16 | 2021 | 367725 | 0.10 | Why? |
| Reproducibility of Results | 3 | 2021 | 11304 | 0.10 | Why? |
| Aged | 11 | 2021 | 215776 | 0.10 | Why? |
| Diagnostic Tests, Routine | 1 | 2021 | 2643 | 0.10 | Why? |
| Female | 16 | 2021 | 380317 | 0.10 | Why? |
| Staphylococcal Infections | 1 | 2019 | 1099 | 0.10 | Why? |
| Adult | 14 | 2021 | 244371 | 0.09 | Why? |
| Proportional Hazards Models | 1 | 2020 | 6543 | 0.09 | Why? |
| Sensitivity and Specificity | 4 | 2021 | 22971 | 0.09 | Why? |
| Community-Acquired Infections | 1 | 2020 | 2328 | 0.09 | Why? |
| Antifungal Agents | 1 | 2018 | 1828 | 0.08 | Why? |
| Public Health Surveillance | 1 | 2021 | 3129 | 0.08 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2020 | 3607 | 0.08 | Why? |
| Outpatients | 1 | 2020 | 3417 | 0.08 | Why? |
| Smoking | 1 | 2020 | 3358 | 0.08 | Why? |
| Point-of-Care Systems | 1 | 2020 | 2955 | 0.08 | Why? |
| Seasons | 1 | 2019 | 4071 | 0.08 | Why? |
| Young Adult | 7 | 2020 | 93724 | 0.07 | Why? |
| Occupational Diseases | 1 | 2020 | 2787 | 0.07 | Why? |
| Antibodies, Viral | 4 | 2021 | 51949 | 0.07 | Why? |
| State Medicine | 1 | 2018 | 2847 | 0.07 | Why? |
| Hospitals | 2 | 2021 | 11793 | 0.07 | Why? |
| Saliva | 1 | 2020 | 4679 | 0.07 | Why? |
| Polymerase Chain Reaction | 1 | 2019 | 6740 | 0.06 | Why? |
| Prospective Studies | 4 | 2021 | 43301 | 0.06 | Why? |
| Viral Load | 2 | 2021 | 15850 | 0.06 | Why? |
| Algorithms | 1 | 2020 | 7346 | 0.06 | Why? |
| Sepsis | 1 | 2020 | 3517 | 0.06 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.06 | Why? |
| Nasopharynx | 1 | 2021 | 10224 | 0.06 | Why? |
| Models, Theoretical | 1 | 2020 | 6659 | 0.06 | Why? |
| C-Reactive Protein | 1 | 2018 | 7972 | 0.06 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 11367 | 0.06 | Why? |
| Infant, Newborn | 2 | 2020 | 23105 | 0.06 | Why? |
| Mobile Applications | 1 | 2017 | 3032 | 0.05 | Why? |
| Predictive Value of Tests | 3 | 2020 | 9537 | 0.05 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 13720 | 0.05 | Why? |
| Seroepidemiologic Studies | 3 | 2021 | 10017 | 0.05 | Why? |
| Kidney Transplantation | 1 | 2020 | 5397 | 0.05 | Why? |
| Propionibacterium acnes | 1 | 2019 | 19 | 0.05 | Why? |
| Wrist | 1 | 2019 | 37 | 0.05 | Why? |
| Health Policy | 1 | 2020 | 6242 | 0.05 | Why? |
| Infant | 2 | 2020 | 30274 | 0.05 | Why? |
| Wrist Joint | 1 | 2019 | 34 | 0.05 | Why? |
| Obesity | 1 | 2020 | 7388 | 0.05 | Why? |
| Shoulder | 1 | 2019 | 96 | 0.05 | Why? |
| Mycoplasma pneumoniae | 1 | 2021 | 233 | 0.05 | Why? |
| Penicillin V | 1 | 2018 | 10 | 0.05 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.05 | Why? |
| Penicillin G | 1 | 2018 | 14 | 0.05 | Why? |
| Child, Preschool | 2 | 2020 | 36283 | 0.05 | Why? |
| Reagent Strips | 1 | 2018 | 129 | 0.04 | Why? |
| Mendelian Randomization Analysis | 1 | 2020 | 317 | 0.04 | Why? |
| Biomarkers | 2 | 2018 | 23361 | 0.04 | Why? |
| Genetic Association Studies | 1 | 2020 | 559 | 0.04 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.04 | Why? |
| Audiovisual Aids | 1 | 2018 | 138 | 0.04 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.04 | Why? |
| Severity of Illness Index | 2 | 2020 | 48226 | 0.04 | Why? |
| Adolescent | 3 | 2020 | 86841 | 0.03 | Why? |
| Administration, Intravenous | 1 | 2018 | 1115 | 0.03 | Why? |
| Focus Groups | 1 | 2018 | 811 | 0.03 | Why? |
| Dyslipidemias | 1 | 2020 | 791 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.03 | Why? |
| Interrupted Time Series Analysis | 1 | 2017 | 868 | 0.03 | Why? |
| Risk Assessment | 1 | 2017 | 25439 | 0.03 | Why? |
| Child | 2 | 2020 | 70012 | 0.03 | Why? |
| Infection Control | 2 | 2020 | 23131 | 0.03 | Why? |
| Oropharynx | 1 | 2020 | 1581 | 0.03 | Why? |
| Coronavirus | 1 | 2021 | 18339 | 0.03 | Why? |
| Intensive Care Units | 1 | 2018 | 29594 | 0.03 | Why? |
| Patient Participation | 1 | 2018 | 829 | 0.03 | Why? |
| Educational Status | 1 | 2017 | 1451 | 0.03 | Why? |
| DNA, Viral | 1 | 2020 | 2521 | 0.02 | Why? |
| Minority Groups | 1 | 2020 | 1631 | 0.02 | Why? |
| Hand Hygiene | 1 | 2020 | 1493 | 0.02 | Why? |
| Phenotype | 1 | 2020 | 4037 | 0.02 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2018 | 2259 | 0.02 | Why? |
| Reconstructive Surgical Procedures | 1 | 2018 | 860 | 0.02 | Why? |
| Acute Disease | 1 | 2020 | 6029 | 0.02 | Why? |
| Body Mass Index | 1 | 2020 | 4306 | 0.02 | Why? |
| Survival Analysis | 1 | 2020 | 7592 | 0.02 | Why? |
| Carrier State | 1 | 2019 | 2100 | 0.02 | Why? |
| Patient Isolation | 1 | 2020 | 3182 | 0.02 | Why? |
| Motivation | 1 | 2017 | 1640 | 0.02 | Why? |
| Pilot Projects | 1 | 2018 | 5182 | 0.02 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.02 | Why? |
| Telemedicine | 1 | 2017 | 25032 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2020 | 4027 | 0.02 | Why? |
| Health Personnel | 3 | 2021 | 29646 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 7868 | 0.02 | Why? |
| Attitude to Health | 1 | 2018 | 2002 | 0.02 | Why? |
| Transplant Recipients | 1 | 2020 | 4982 | 0.02 | Why? |
| Guideline Adherence | 1 | 2017 | 2309 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.02 | Why? |
| Decision Making | 1 | 2018 | 3132 | 0.02 | Why? |
| Socioeconomic Factors | 1 | 2020 | 8495 | 0.02 | Why? |
| Surgical Procedures, Operative | 1 | 2019 | 2662 | 0.02 | Why? |
| Length of Stay | 1 | 2020 | 11042 | 0.02 | Why? |
| Follow-Up Studies | 1 | 2020 | 17020 | 0.01 | Why? |
| Case-Control Studies | 1 | 2020 | 17671 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2020 | 6166 | 0.01 | Why? |
| Prevalence | 1 | 2020 | 25773 | 0.01 | Why? |
| Biomedical Research | 1 | 2017 | 5270 | 0.01 | Why? |
| Hospital Mortality | 1 | 2020 | 22087 | 0.01 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.01 | Why? |
| Treatment Outcome | 1 | 2020 | 51732 | 0.01 | Why? |
| Emergency Service, Hospital | 1 | 2018 | 14232 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2020 | 53120 | 0.01 | Why? |
| Risk Factors | 1 | 2020 | 71621 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2018 | 43792 | 0.01 | Why? |
Moore's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(173)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(156)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_